)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Neumora Therapeutics
Neumora Therapeutics (NMRA) investor relations material
Neumora Therapeutics Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary11 Feb, 2026
Key data and clinical updates
Presented new phase I-B data for NMRA-511 in Alzheimer's agitation, showing strong clinical effects and favorable safety, with plans to test higher doses in 2026 and move to pivotal studies in 2027.
NMRA-511 demonstrated robust efficacy, especially in patients with elevated anxiety, with effect sizes surpassing comparators and consistent results across multiple clinical scales.
Safety profile remains favorable, with no significant concerns; a single hyponatremia SAE was deemed confounded and not mechanistically linked.
Plans include a MAD extension cohort, transition to a QD extended-release formulation, and extension of IP protection to 2046.
Competitive landscape includes other V1a antagonist programs, but NMRA-511 is positioned as highly differentiated.
Pipeline and program strategy
NLRP3 inhibitor NMRA-215 is being advanced for obesity, with a focus on CNS penetration to drive weight loss and cardioprotective effects.
Upcoming biomarker data will focus on demonstrating brain IC90 coverage and cardioprotective markers, with first-in-human studies expected in the first half of the year.
Commercial strategy for NMRA-215 targets combination with GLP-1s and maintenance settings, with potential for monotherapy as physician comfort grows.
Additional CNS-penetrant and peripherally restricted NLRP3 compounds are in development to address pricing and indication-specific needs.
Other pipeline updates and financials
Two M4 PAM compounds (NMRA-861, NMRA-898) are in phase 1; a mid-year update will determine which advances to proof-of-concept, with decision criteria including CNS penetration and PK variability.
KOASTAL 2 and 3 data for navacaprant are expected in Q2, with increased enrollment to maximize study power and quality.
Current cash position supports operations into Q3 2027, covering all major upcoming catalysts.
NMRA-511: Strategy for anxiety population
NMRA-215: CNS penetration for weight loss
NMRA-215: Neuro indication strategy
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Neumora Therapeutics earnings date
Q4 20253 Mar, 2026
Neumora Therapeutics
Next Neumora Therapeutics earnings date
Q4 20253 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Neumora Therapeutics Inc., known as NMRA, is a clinical-stage biopharmaceutical company focused on the development of therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. Founded in 2019 and formerly known as RBNC Therapeutics, Inc., Neumora aims to redefine neuroscience drug development by integrating data science with neuroscience to pioneer precision medicines for complex brain diseases. The company's pipeline includes various programs at different stages of clinical trials targeting diseases such as major depressive disorder, agitation associated with dementia due to Alzheimer's disease, schizophrenia, amyotrophic lateral sclerosis, and Parkinson's disease, among others. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage